Image Place holder

Hung T. Khong, MD


Specialty: Medical Oncology
Program: Breast Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Khong's clinical interests include breast cancer and cancer immunotherapy.  He specializes in the treatment of breast cancer of all stages.  He is interested in combining treatment methods such as chemotherpy or radiotherapy with immunotherapy and chemotherapy with targeted therapy. Dr. Khong has developed several innovative clinical trials for the neoadjuvant treatment of stages II and II breast cancer, and first-line therapy for metastatic breast cancer.  He brings to Moffitt and innovative clinical trial that is the first in the country to combine endocrine therapy and checkpoint inhibitors in the neoadjuvant treatment of hormone-receptor positive breast cancer.

Education & Training

Board Certification:

  • Medical Oncology

Fellowship:

  • National Cancer Institute - Medical Oncology
  • National Cancer Institute - Surgery Branch

Residency:

  • Baylor College of Medicine - Internal Medicine Program

Medical School:

  • Temple University School of Medicine - MD
Participating Trials

CLINICAL TRIAL 18503
STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Condition: Thoracic
Intervention: Entrectinib
Open

CLINICAL TRIAL 18825
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients with Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Condition: Multiple
Intervention: XMT-1522
Open

CLINICAL TRIAL 18079
Combination Immunotherapy with Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Condition: Breast
Intervention: E75; GM-CSF; Herceptin (Trastuzumab); Leukine (GM-CSF); Placebo; sargramostatin (GM-CSF)
Open

CLINICAL TRIAL 19105
A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with an Antibody Targeting the PD-1/PD-L1 Pathway in HLA-A2+ Subjects Who Have Completed Initial Standard Treatment of Stage II or III Triple Negative Breast Cancer (TNBC)
Condition: Breast
Intervention: AMP-514 (Durvalumab); Durvalumab; MEDI4736 (Durvalumab); PVX-410
Open

CLINICAL TRIAL 18621
A Phase 1/2 Study of Talimogene laherparepvec in Combination with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Condition: Breast
Intervention: Adriamycin (doxorubicin); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec); Taxol (paclitaxel); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; paclitaxel
Open

CLINICAL TRIAL 18936
A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients with HER-2 Positive Breast Cancer
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab; Taxol (paclitaxel); Trastuzumab; interferon gamma (Actimmune); paclitaxel; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 18810
Phase 1b Study To Assess The Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole Or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (Mbc)
Condition: Breast
Intervention: 772256 (Palbociclib); Faslodex (fulvestrant); Femara (Letrozole); Gedatolisib; Letrozole; PF-05212384 (Gedatolisib); Palbociclib; fulvestrant
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D. Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res. 2017 Oct;27(5):477-484. Pubmedid: 28800031. Pmcid: PMC5583702.
  • Werner TL, Ray A, Lamb JG, VanBrocklin M, Hueftle K, Cohen AL, Beck AC, Buys SS, Dyess DL, Butler TW, Dumlao TL, Neumayer L, Khong HT. A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. Clin Breast Cancer. 2017 Nov;17(7):503-509. Pubmedid: 28579139.
  • Bowen RC, Little NAB, Harmer JR, Ma J, Mirabelli LG, Roller KD, Breivik AM, Signor E, Miller AB, Khong HT. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget. 2017 May;8(19):32171-32189. Pubmedid: 28418870. Pmcid: PMC5458276.
  • Lawson BO, Khong HT. Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature. Anticancer Res. 2017 Mar;37(3):1365-1368. Pubmedid: 28314304.
  • Bowen RC, Hahn AW, Butler TW, Khong HT. Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy. Mol Clin Oncol. 2017 Jan;6(1):122-124. Pubmedid: 28123744. Pmcid: PMC5245156.
  • Cohen AL, Ray A, Van Brocklin M, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, Khong HT. A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. Oncotarget. 2017 Aug;8(32):52413-52419. Pubmedid: 28881739. Pmcid: PMC5581038.
  • Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget. 2016 Sep;7(39):64390-64399. Pubmedid: 27391442. Pmcid: PMC5325451.
  • Liu Z, Smith KR, Khong HT, Huang J, Ahn EE, Zhou M, Tan M. miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20. Oncotarget. 2016 Nov;7(48):78667-78679. Pubmedid: 27637078. Pmcid: PMC5346668.
  • Cohen AL, Ray A, Van Brocklin M, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, Khong HT. A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. Oncotarget. 2016 Dec. Pubmedid: 28039455.
  • Ray A, Khong B, Khong HT. A Case Report of Pneumocystis Jiroveci Pneumonia in a Patient with Metastatic Breast Cancer. Anticancer Res. 2016 Dec;36(12):6673-6676. Pubmedid: 27920001.
  • Howell PM, Liu Z, Khong HT. Demethylating Agents in the Treatment of Cancer. Pharmaceuticals (Basel). 2010 Jul;3(7):2022-2044. Pubmedid: 27713340. Pmcid: PMC4036667.
  • Wang Y, Radfar S, Liu S, Riker AI, Khong HT. Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma. BMC Med. 2010 Feb;8:14. Pubmedid: 20163701. Pmcid: PMC2839965.